Form 4: Biogen EVP Gregory Reports Routine Stock Transactions

Biogen's EVP of Human Resources, Ginger Gregory, reported the acquisition and disposition of common stock related to restricted stock unit vesting and tax withholdings.

Summary

• Ginger Gregory, Executive Vice President of Human Resources at Biogen Inc. (BIIB), reported multiple transactions on February 6, 2026.
• Acquired a total of 7,183 shares of common stock through the vesting of Restricted Stock Units (RSUs) from grants made on February 8, 2023, February 7, 2024, and February 6, 2025.
• Disposed of a total of 2,589 shares of common stock at a price of $201.18 per share to cover tax withholding obligations associated with the RSU vesting.
• Following these transactions, Ginger Gregory's direct beneficial ownership of Biogen common stock is 22,358.7673 shares.
• The reported beneficial ownership also includes 166.6667 shares acquired under the Biogen Inc. employee stock purchase plan on March 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine executive compensation events and continued equity ownership, which aligns with standard corporate governance practices and executive retention.

Positives

• Vesting of Restricted Stock Units (RSUs) indicates the executive's continued tenure and receipt of equity compensation, aligning executive interests with shareholders.
• The executive's beneficial ownership of common stock remains substantial at 22,358.7673 shares, demonstrating ongoing investment in the company.

Negatives

• A total of 2,589 shares were disposed of at $201.18 per share to cover tax obligations related to RSU vesting, which reduces the executive's direct shareholding.

Future Outlook

The filing primarily reports historical transactions and does not contain explicit forward-looking statements or guidance beyond the scheduled vesting of existing restricted stock units.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executive equity compensation. They reflect standard practices for incentivizing management through long-term equity awards and managing tax liabilities upon vesting, common across the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and ownership, indicating alignment of interests between management and shareholders.
• Employees: Reflects standard equity compensation practices for executives, which can serve as a benchmark for broader employee incentive programs.

Next Steps

• Future installments of Restricted Stock Units (RSUs) granted on February 7, 2024, are scheduled to vest annually until February 7, 2027.
• Future installments of Restricted Stock Units (RSUs) granted on February 6, 2025, are scheduled to vest annually until February 6, 2028.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting of Restricted Stock Units and subsequent tax-related share dispositions. It does not contain new material information that would alter the fundamental investment thesis for Biogen Inc., thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Biogen, BIIB, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, RSU, Equity Compensation, Stock Transaction